Shaggy Mane, Coprinus Mushroom Powder fruitbody powder standardized to Pure Beta Glucan >25% is a Coprinus comatus ingredient for food supplements and functional foods that need a clear fruitbody beta-glucan marker instead of a generic mushroom blend. Its best commercial fit is metabolic-wellness and glucose-support mushroom concepts in capsules, tablets, sachets, nutrition powder blends, and multi-mushroom formulas. Quality limits are controlled for moisture <9.0%, total ash <9.0%, heavy metals, pesticide residue <LOQ, and the stated microbiological limits in the COA.

*Study doses in the literature may use species-specific powders or extracts rather than this exact batch. For this shop SKU, a practical general range is 500-3000 mg/day unless the finished formula supports a different serving size.

How it works

1. Standardized beta-glucan marker: The beta-glucan specification above 25% gives formulators a measurable polysaccharide marker for batch control and claim discipline.
2. Species-specific fruitbody matrix: Shaggy Mane is best framed through broader mushroom-matrix and polysaccharide/fiber context rather than as a single defined pharmaceutical active.
3. Finished-product serving reality: For mushroom powders, the main technical decision is usually realistic serving design and sensory fit, not exotic chemical stabilization.

How to use and key cautions

• Usual supplemental range: A practical general range is 500-3000 mg/day (0.5-3.0 g/day).
• Best product formats: Best fit is capsules, tablets, sachets, nutrition powder blends, and multi-mushroom formulas; choose formats that can deliver the target serving without making the product too bulky or hard to mix.
• Formulation advice: Best fit is in capsules, tablets, and sachets; use larger serving forms if the product narrative depends on a meaningful mushroom dose.
• Processing and taste: Preblend carefully, protect from humidity, and keep flavor systems practical because the ingredient is not intended for elegant clear-drink presentation.
• Who should use extra caution: Use medical oversight for people with diabetes or on glucose-lowering medication, and avoid any public disease-treatment implication.